Colliers Houston's president David Houston and VP Milt Charbonneau, as well as Pyramid Brokerage Co.'s president Maureen DeJure Wilson, and associate broker Kevin Besser, will lead the marketing program on behalf of the owner, P&G Pharmaceuticals, under an agreement with P&G Pharmaceuticals. Houston tells GlobeSt.com that the building is on the market because Procter & Gamble has decided to consolidate some of its operations.

There is no asking price, Houston says, and he could not provide a comp value at this time, however he did note that there is no price partly because of the value-add that the facility has to offer. Building 42 contains analytical laboratories, administrative offices, a suite of laboratories for the production and analysis of radiochemical compounds, two videoconference suites, the cafeteria and the library. Building 46 contains chemical development laboratories, chemical development pilot plants, a suite of cGMP kilo labs, a suite of cGMP clinical drug product pilot plants, a cGMP warehouse, and offices. Building 99 was originally constructed as an animal research facility, and has since been renovated for non-cGMP pharmaceutical development laboratories and pilot plants. Building 99 also contains the IT LANs and offices. Buildings 1 and 7 are Active Pharmaceutical Ingredient manufacturing buildings. There are also numerous outbuildings, including warehouses, solvent buildings, boiler house, well houses, and storage buildings and offices.

"Not only does the facility have equipment available, it is completely operational and all permits are in place," he says. Houston adds that the building has been "immaculately maintained" and also offers buyers extra land "to do with what they like." Also, he says, the town is eager to get someone in and help them out as best they can. Other amenities include two videoconference suites, chemical development laboratories, purified water, electronic security and guardhouse, cafeteria, library, an updated sprinkler system and a 37,400-sf parking lot.